Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by AGF Management Ltd.

AGF Management Ltd. lifted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 281.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,277 shares of the biopharmaceutical company’s stock after buying an additional 942 shares during the quarter. AGF Management Ltd.’s holdings in Regeneron Pharmaceuticals were worth $910,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of REGN. Wealthfront Advisers LLC raised its holdings in Regeneron Pharmaceuticals by 68.5% in the 4th quarter. Wealthfront Advisers LLC now owns 15,990 shares of the biopharmaceutical company’s stock valued at $11,390,000 after acquiring an additional 6,501 shares during the last quarter. Cornerstone Advisors LLC grew its position in shares of Regeneron Pharmaceuticals by 31.7% in the fourth quarter. Cornerstone Advisors LLC now owns 7,900 shares of the biopharmaceutical company’s stock valued at $5,627,000 after purchasing an additional 1,900 shares during the period. Mcdonald Capital Investors Inc. CA increased its stake in Regeneron Pharmaceuticals by 24.7% in the fourth quarter. Mcdonald Capital Investors Inc. CA now owns 170,180 shares of the biopharmaceutical company’s stock valued at $121,224,000 after purchasing an additional 33,727 shares during the last quarter. Independent Advisor Alliance increased its stake in Regeneron Pharmaceuticals by 117.3% in the fourth quarter. Independent Advisor Alliance now owns 478 shares of the biopharmaceutical company’s stock valued at $340,000 after purchasing an additional 258 shares during the last quarter. Finally, Johnson Investment Counsel Inc. lifted its position in Regeneron Pharmaceuticals by 73.9% during the fourth quarter. Johnson Investment Counsel Inc. now owns 487 shares of the biopharmaceutical company’s stock worth $347,000 after buying an additional 207 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. Leerink Partnrs raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 5th. Canaccord Genuity Group lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 17th. Wells Fargo & Company cut their price target on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a research note on Friday, January 10th. Wolfe Research assumed coverage on shares of Regeneron Pharmaceuticals in a research note on Friday, November 15th. They set an “outperform” rating and a $1,150.00 price objective for the company. Finally, Truist Financial cut their target price on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a research report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $973.13.

Regeneron Pharmaceuticals Trading Down 2.0 %

NASDAQ:REGN opened at $666.87 on Friday. The stock has a market cap of $72.91 billion, a price-to-earnings ratio of 17.42, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27. Regeneron Pharmaceuticals, Inc. has a one year low of $642.00 and a one year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The business’s 50-day simple moving average is $694.91 and its 200 day simple moving average is $836.31.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same period in the prior year, the company posted $11.86 EPS. Regeneron Pharmaceuticals’s quarterly revenue was up 10.3% on a year-over-year basis. As a group, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.53%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.